S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
S&P 500   4,279.05 (-0.21%)
DOW   33,357.21 (-0.45%)
QQQ   360.36 (+0.58%)
AAPL   173.71 (+1.46%)
MSFT   318.32 (+0.81%)
META   305.07 (+1.62%)
GOOGL   133.52 (+2.03%)
AMZN   128.98 (+1.46%)
TSLA   249.27 (-0.38%)
NVDA   448.11 (+3.02%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.23 (-0.57%)
T   14.86 (-1.07%)
F   12.33 (-0.72%)
MU   67.71 (-0.47%)
CGC   0.77 (-1.05%)
GE   109.60 (-0.86%)
DIS   80.93 (-0.15%)
AMC   7.93 (-0.75%)
PFE   33.19 (+0.06%)
PYPL   58.79 (+0.56%)
NFLX   380.68 (+0.82%)
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price & News

$346.57
-1.17 (-0.34%)
(As of 10:51 AM ET)
Compare
Today's Range
$342.62
$347.74
50-Day Range
$340.48
$358.40
52-Week Range
$282.21
$367.00
Volume
128,261 shs
Average Volume
1.16 million shs
Market Capitalization
$89.45 billion
P/E Ratio
26.76
Dividend Yield
N/A
Price Target
$367.23

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
5.6% Upside
$367.23 Price Target
Short Interest
Healthy
1.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
1.10mentions of Vertex Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$9.77 M Sold Last Quarter
Proj. Earnings Growth
11.31%
From $13.26 to $14.76 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

191st out of 969 stocks

Pharmaceutical Preparations Industry

66th out of 455 stocks


VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company headquartered in Boston, Massachusetts, was founded in 1989 by Joshua Boger and Kevin J. Kinsella with a vision to revolutionize disease treatments through rational drug design. Their mission is to "transform the way serious diseases are treated," and they have made significant strides in achieving this goal. The company specializes in researching, developing, and commercializing innovative therapies for various medical conditions, primarily focusing on cystic fibrosis. Using cutting-edge science and technology, Vertex has become a leading player in the biotech industry, particularly in the field of precision medicine.

Vertex has overcome challenges and achieved milestones, chronicled in Barry Werth's book "The Billion-Dollar Molecule." Over the years, the company's research and development efforts have primarily targeted viral infections, inflammatory and autoimmune disorders, cancer, and other specialty diseases. Vertex's flagship products are dedicated to treating cystic fibrosis, a genetic condition affecting the respiratory and digestive systems. Notable among these are Kalydeco, the first FDA-approved drug addressing the underlying cause of cystic fibrosis for specific gene mutations, Orkambi, a combination drug for patients with the most common cystic fibrosis mutation (F508del), Symdeko, a dual combination treatment for certain gene mutations and Trikafta, a groundbreaking triple-combination therapy for cystic fibrosis.

The company's target market consists of patients suffering from serious diseases, especially those with cystic fibrosis and other genetic disorders. Vertex's therapies are designed to cater to specific gene mutations, offering personalized and precision medicine approaches. Key customers include patients with cystic fibrosis and their families, healthcare providers specializing in genetic diseases and health systems, and insurers providing access to these life-changing therapies. Vertex Pharmaceuticals has achieved significant financial growth in recent years, reflecting its successful drug development efforts. Impressive revenue metrics and robust earnings metrics indicate the company's ability to translate its research into profitable treatments efficiently. The company's strong profit margin metrics also showcase its effective financial management.

The positive financial performance has driven the company's stock price upwards, reflecting investor confidence in Vertex's ability to deliver innovative therapies and capitalize on unmet medical needs. The company's strong financials, expanding product pipeline, and contributions to cystic fibrosis treatment have justified its favorable valuation compared to industry peers. Vertex Pharmaceuticals' successful development and commercialization of Trikafta have been key drivers behind the company's positive valuation and investor sentiment. The drug's significant impact on patients and its potential for continued growth have attracted investors seeking exposure to the dynamic biopharmaceutical sector.

As Vertex explores gene-editing therapies in collaboration with CRISPR Therapeutics and Arbor Biotechnologies, investors view the company as a strategic player in addressing significant unmet medical needs. The company's commitment to research and development further solidifies investor confidence in its long-term prospects.

Vertex Pharmaceuticals has demonstrated resilient stock performance. Investors recognize the company's value as a pioneer in the biotech industry, with a focus on precision medicine and transformative therapies. The company's dedication to research and its successful commercialization of existing drugs underscores its strategic positioning in the market.

As Vertex continues to expand its product pipeline and explore new treatment avenues, investors remain optimistic about the company's growth potential. The company's innovative research collaborations, particularly in gene-editing therapies, are expected to drive further positive investor sentiment. In the broader industry, Vertex Pharmaceuticals is well-positioned relative to its peers. Its specialization in precision medicine and groundbreaking therapies for genetic diseases sets it apart, giving the company a competitive advantage. Vertex's successful track record and commitment to addressing unmet medical needs further reinforce its strong position in the market.

While Vertex Pharmaceuticals has achieved significant milestones, the company faces certain risks and challenges. Regulatory hurdles, competitive pressures, and the need for continued investment in research and development are potential factors that may impact its future growth. However, the company's risk management strategies and prudent financial management are designed to mitigate potential risks and position Vertex for continued success. As the company continues to innovate and expand its product portfolio, it is expected to maintain its strong position in the biopharmaceutical industry.

VRTX Price History

VRTX Stock News Headlines

Got $1,000? 2 No-Brainer Stocks to Buy
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
A Total Return Superstar: Vertex Pharmaceuticals
Better Bull Market Buy: CRISPR vs. Medtronic Stock
2 Top Biotech Stocks to Buy in September
1 Top Pharma Growth Stock to Buy Today and Hold Forever
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings
8/01/2023
Today
10/02/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
4,800
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$367.23
High Stock Price Forecast
$456.00
Low Stock Price Forecast
$296.00
Forecasted Upside/Downside
+5.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
18 Analysts

Profitability

Net Income
$3.32 billion
Pretax Margin
45.31%

Debt

Sales & Book Value

Annual Sales
$8.93 billion
Cash Flow
$13.99 per share
Book Value
$54.20 per share

Miscellaneous

Free Float
257,063,000
Market Cap
$89.75 billion
Optionable
Optionable
Beta
0.51

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jeffrey Marc Leiden M.D. (Age 67)
    Ph.D., Exec. Chairman
    Comp: $92.93k
  • Dr. Reshma Kewalramani FASNDr. Reshma Kewalramani FASN (Age 50)
    M.D., CEO, Pres & Director
    Comp: $5.22M
  • Mr. Charles F. Wagner Jr.Mr. Charles F. Wagner Jr. (Age 55)
    Exec. VP & CFO
    Comp: $2.06M
  • Mr. Stuart A. Arbuckle B.Sc.Mr. Stuart A. Arbuckle B.Sc. (Age 57)
    Exec. VP & COO
    Comp: $2.7M
  • Dr. David M. Altshuler M.D. (Age 58)
    Ph.D., Exec. VP of Global Research & Chief Scientific Officer
    Comp: $2.03M
  • Ms. Kristen C. AmbroseMs. Kristen C. Ambrose (Age 46)
    Sr. VP & Chief Accounting Officer
  • Mr. Mike Tirozzi
    SVP and Chief Information & Data Officer
  • Susie Lisa
    Sr. VP of Investor Relations
  • Mr. Damian W. Wilmot Esq. (Age 47)
    Sr. VP, Chief Risk and Compliance Officer
  • Mr. Jonathan Biller J.D. (Age 59)
    Exec. VP & Chief Legal Officer













VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VRTX shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2023?

18 analysts have issued 1 year target prices for Vertex Pharmaceuticals' stock. Their VRTX share price forecasts range from $296.00 to $456.00. On average, they expect the company's share price to reach $367.23 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2023?

Vertex Pharmaceuticals' stock was trading at $288.78 on January 1st, 2023. Since then, VRTX stock has increased by 20.4% and is now trading at $347.74.
View the best growth stocks for 2023 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its earnings results on Tuesday, August, 1st. The pharmaceutical company reported $3.53 EPS for the quarter, topping the consensus estimate of $3.47 by $0.06. The pharmaceutical company earned $2.49 billion during the quarter, compared to analyst estimates of $2.41 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 24.05% and a net margin of 35.40%.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $9.70 billion-$9.80 billion, compared to the consensus revenue estimate of $9.75 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $347.74.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $89.75 billion and generates $8.93 billion in revenue each year. The pharmaceutical company earns $3.32 billion in net income (profit) each year or $12.95 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 4,800 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -